Navigation Links
New Stem Cell Technology to Improve Drug Safety
Date:4/22/2009

TOKYO, April 22 /PRNewswire-Asia/ -- Drug side effects are a major problem for the drug industry. Even very rare events, if serious enough, can warrant drug withdrawal. Unfortunately, these problems often emerge only after a drug has been used by thousands or even millions of patients.

Identifying drugs that can trigger heart attacks before they reach the clinic is a major focus of ReproCELL. Current cardiotoxicity tests, especially at early stages of drug development, tend to focus on one aspect of heart cell function -- the hERG ion channel. But there are a whole range of other ion channels, as well as other possible issues, which hERG tests miss. ReproCELL has developed the QTempo assay to comprehensively screen cardiac ion channels and other factors to significantly reduce the chances of a cardiotoxic drug reaching the clinic.

The QTempo test uses beating heart cells grown in a dish from stem cells. Similar to an ECG, these cells are attached to electrodes to measure their electrical activity, which is monitored as experimental drugs are added. Until recently, ethical issues surrounding human embryonic stem cells, had restricted QTempo to monkey heart cells. Now, under a license agreement between ReproCELL and iPS Academia, a human version of this new test is available. This is the first ever commercial test using iPS technology.

ReproCELL's CEO, Chikafumi Yokoyama, commented "Drug companies usually prefer to see in-vitro data from human cells. Basing the QTempo assay around human heart cells makes the test more clinically relevant. Not only will the improved test contribute to patient safety, it will help reduce the huge amounts of effort drug companies waste on developing drugs that are later withdrawn".

iPS Academia, KYOTO, JAPAN, was established to license iPS technology developed in the Kyoto lab of Shinya Yamanaka. The iPS (induced Pluripotent stem cell) technology is a revolutionary new way of making embryonic-like stem cells from normal adult tissue, typically skin cells.

ReproCELL, TOKYO, JAPAN, offers stem cell-focused products and services to researchers and health professionals. ReproCELL products are used in many of the world's leading stem cell labs and were used in the development of the world's first human iPS cells. ReproCELL has applied its stem cell expertise to develop pre-clinical and clinical diagnostic tests to improve the development of drugs and monitoring of patients.

For further information, please visit http://www.reprocell.net .


'/>"/>
SOURCE ReproCELL Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Quantum light beams good for fast technology
2. New Smart Technology Makes Patient Data Collection Easier, More Efficient
3. Align Technology Executive to Present at Upcoming Financial Conferences
4. Pioneer Surgical Technology Hires Vice President of New Business Development
5. Purdue researchers develop technology to detect cancer by scanning surface veins
6. Creative Technology Services Enhances its Global Competitiveness with Additional Regulatory Certifications
7. University of Wisconsin Hospitals and Clinics Complete System-Wide Conversion to Masimo SET Pulse Oximetry Technology
8. Patent Reform Legislation Threatens Americas Leadership in Medical Technology Innovation
9. Stevens Health, Technology and Society roundtable: Sept. 19
10. Microbiotic technology developed for microinjection of zebrafish embryos
11. Proven Terumo Coronary Guidewire Technology Is Now Available in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... ... Room (ER) on Wednesday, August 16, to community partners. The newly renovated ER ... “Fast Track” area for minor emergencies, eight semi-private rooms to deliver patient results, ...
(Date:8/17/2017)... ... 17, 2017 , ... An August 2 article on NextShark discusses ... largely influenced by the growing popularity of “pretty boys” in both K-Pop and television ... of male appearance are changing not only in the Asian nation, where plastic surgery ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... ... care professionals, today announced that it has raised $1.675 M in seed funding ... Rethink Education, Lumina Foundation, and Techstars Venture Capital Fund are the company’s primary ...
(Date:8/17/2017)... ... August 17, 2017 , ... Momkus McCluskey Roberts LLC ... Parks is a member of the firm’s Commercial Litigation and Employment Law groups. , ... wealth of knowledge in matters of employment litigation, commercial litigation and business disputes. Her ...
(Date:8/17/2017)... ... 2017 , ... Finalists in the 2017 (second annual) ... awards recognize the world’s best employers and the human resources professionals, teams, achievements ... to work. , A diverse group of organizations and individuals around the world ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... its financial results for the second quarter ended June ... second quarter 2017 and to date: ... programs for the Company,s lead project, BL-8040: ... with BL-8040 as novel stem cell mobilization treatment for ...
(Date:8/7/2017)... Insightin Health, provider of data-driven decision-making ... announced the selection of Michael Wood ... as of February 2017. In this role, Wood will ... our clients. Wood brings with him more than ... analytics within the healthcare industry. Wood formerly served ...
(Date:8/7/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ) today ... effective Aug. 7, 2017. ... interests and will serve as president emeritus during a planned, ... in multiple leadership roles since he joined Diplomat with the ... provided decisive, strategic leadership which continues to benefit our patients ...
Breaking Medicine Technology: